Search results
Showing results for
Infinitopes, a clinical-stage cancer vaccine Biotechnology company, today announced the appointment of world-leading scientific innovator Dr Kristen Hege to its Scientific Advisory Board (SAB). This strategic appointment comes at a pivotal time after the launch of the VISTA trial, the first dosing in patients of Infinitopes’ lead precision cancer vaccine candidate, ITOP1. ITOP1 is a therapeutic vaccine designed to prevent recurrence in oesophageal cancer – a major area of unmet clinical need.
Infinitopes expands Scientific Advisory Board with world-leading clinician-scientist Dr Kristen Hege
27 July 2026
Infinitopes, a clinical-stage cancer vaccine Biotechnology company, today announced the appointment of world-leading scientific innovator Dr Kristen Hege to its Scientific Advisory Board (SAB). This strategic appointment comes at a pivotal time after the launch of the VISTA trial, the first dosing in patients of Infinitopes’ lead precision cancer vaccine candidate, ITOP1. ITOP1 is a therapeutic vaccine designed to prevent recurrence in oesophageal cancer – a major area of unmet clinical need.
Moa announces Series C funding round
22 July 2026
Moa Technology (“Moa”), an agricultural biotechnology company focused on discovering novel mode of action herbicides, announces a £22.2 million Series C financing round, co-led by Oxford Science Enterprises (“OSE”) and Supernova Invest (“Supernova”).
Infinitopes doses first patient with precision off-the-shelf therapeutic cancer vaccine ITOP1
22 July 2026
VISTA trial evaluates a precision therapeutic vaccine in an immunologically favourable treatment window for oesophageal cancer.
Oxford Cancer Analytics joins major collaborative study to transform lung cancer screening in the UK
20 July 2026
Thousands of people in Cheshire and Merseyside are being invited to take part in pioneering Liverpool-led research that could shape the future of lung cancer screening.
Theolytics announces that it has relocated to new, state‑of‑the‑art facilities at ARC Oxford, a growing science and innovation campus close to Oxford’s world‑class research institutes, teaching hospitals and university
15 July 2026
Theolytics, a clinical‑stage biotechnology company developing next‑generation oncolytic immunotherapies, announces that it has relocated to new, state‑of‑the‑art facilities at ARC Oxford, a growing science and innovation campus close to Oxford’s world‑class research institutes, teaching hospitals and university. The company joins a thriving community of more than 30 science and technology companies at ARC Oxford, further strengthening the campus’ position as a hub for cutting‑edge innovation.
Alchemab Therapeutics announce biggest ever life sciences investment from British Business Bank to advance its AI-enabled clinical pipeline of next generation human-derived antibodies
8 July 2026
Clinical-stage biotech Alchemab Therapeutics has extended its series A financing with a £25 million (USD $34m) investment from the British Business Bank – the Bank’s largest investment in a life sciences company to date. The funding will enable the company to build its clinical pipeline and grow its proprietary unique antibody dataset to more than a billion sequences.
Moa and Corteva sign collaboration deal
6 July 2026
Moa Technology and Corteva collaborate to accelerate discovery of novel herbicides
Never mind the heatwave, competition at our seventh annual Pitch Battle was hot!
1 July 2026
The sun beat down in the June heatwave as our annual Pitch Battle took place recently, matching the fierce tenant competition to win the coveted Best Pitch prize, sponsored by The Oxford Science Park (TOSP). The Small But Mighty prize, open to our smaller tenants located in our shared Innovation Labs, was sponsored for the first time this year, by ThermoFisher Scientific. Creating a total prize pot of £3,500, the stakes were high as the event started.
BioEscalator Portfolio 2026
25 June 2026
The second edition of our Portfolio, a valuable guide to the BioEscalator tenant community for investors, partners and anyone interested in biomedical innovation, has been published. With an introduction from Charlotte Casebourne Stock, Executive Partner at Yarvie and co-founder of Theolytics, plus profiles of 14 companies creating the future of healthcare, it brings an exciting insight into the R&D taking place here.
Newly inked strategic collaboration between Entelo Bio and Atrogi to advance the future of human physical resilience
15 June 2026
This partnership brings together Entelo Bio's groundbreaking isoform-resolved AI discovery platform and Atrogi's clinical-stage expertise in muscle-targeted metabolic medicine.
U-Ploid Biotechnologies win Technology Excellence Award at the 2026 Oxfordshire Business Awards (OXBA)
11 June 2026
The BioEscalator was delighted to attend the awards evening as guests of The Oxford Science Park. The evening was made even more special by BioEscalator tenant U-Ploid Biotechnologies taking home the Technology Excellence Award. Congratulations to the entire team on this well-deserved recognition of their innovative work and achievements.
BioEscalator Bulletin - Summer 2026
3 June 2026
Stay informed with the latest BioEscalator updates, tenant and alumni news in the Summer 2026 edition of the BioEscalator Bulletin.
The BioEscalator welcomes mitochondrial transplantation company, Recondria Therapeutics, as new tenant
1 June 2026
Founded by Abhishek Srivastava and Jay Siddharth, Recondria Therapeutics is developing mitochondrial transplantation technology to help damaged or ageing cells recover their energy-producing function.
Biotix joins the BioEscalator community to advance AI-driven drug discovery for skin disease
31 May 2026
Biotix, an AI-enabled biotech focused on the skin microbiome, has relocated from Haverhill Research Park, Cambridge, to the BioEscalator to expand its drug discovery work in inflammatory and immune-mediated skin conditions.
Theolytics’ ongoing US phase 1 OCTOPOD-IP trial of THEO-260 in ovarian cancer to be presented as a trial in progress at ASCO 2026
27 May 2026
THEO-260 is an oncolytic immunotherapy designed to effectively target cancer cells and cancer-associated fibroblasts while inducing immune activation in stroma-rich tumours. The US trial (OCTOPOD-IP) is exploring the safety and tolerability of intraperitoneal delivery of THEO-260 in high-grade serous or endometroid ovarian cancer.
Re-Aim Therapeutics launches with £7m seed financing
17 May 2026
Proceeds to fund the advancement of the company’s lead programme, REA-001, a first-in-class monoclonal antibody that potently and selectively depletes pathogenic T cells for use in a range of autoimmune diseases. The company is progressing a pipeline of antibody-based drugs to deliver transformational changes in the treatment of autoimmune diseases by depleting pathogenic T-cell populations to drive deeper and more durable clinical responses. Iain McGill has been appointed as Independent Chair, and Dhaval Patel has been appointed as Independent Director
Infinitopes appoints Immuno-Oncology Pioneer Jo Brewer as Chief Scientific Officer (CSO) to advance therapeutic pipeline From clinical to commercialisation
11 May 2026
Infinitopes, a biotechnology company developing novel and precision immunotherapy, announces the appointment of Jo Brewer, PhD, as Chief Scientific Officer and interim Chief Operating Officer.
Entelo Bio selected as one of 20 global teams to pioneer AI target discovery in ALS
7 May 2026
Entelo Bio has been named one of 20 global winners of the Longitude Prize on ALS, receiving funding and access to one of the world’s largest ALS datasets to support AI-driven drug target discovery. In this interview, the Oxford spinout shares how the award will accelerate its platform development, collaborative research, and expansion into neuromuscular disease.
Theolytics announces first patient dosed in the OCTOPOD-IP Trial, a US phase 1 trial with THEO-260, a novel oncolytic immunotherapy targeting ovarian cancer
27 April 2026
Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating intraperitoneal (IP) administration of THEO-260 for the treatment of women with Platinum-Resistant Ovarian Cancer (PROC) (NCT07211659).
The life of a BioEscalator apprentice, featuring geology, mental health and award nominations
27 April 2026
Our apprentices, Billy Pullen & Becson Ody, bring ideas, initiative and new ways of doing things to the BioEscalator. This month, we've seen more examples of their drive and understanding of the workplace.